



Brussels, 24<sup>th</sup> September 2014

Dear Prof Stahel,

We are glad that you took the time to reply to our email, and to know that you share our concern and disappointment regarding the access of non-prescribers to the ESMO exhibition, caused by the Spanish interpretation of the pertinent EU directives and national regulations.

As you rightfully mention in your email, we fully understand the reasons behind this incident and we are more than glad to join you on the 29th to discuss a possible joint way forward.

We fully acknowledge, in fact, your transparency and helpfulness, and we will be glad to support ESMO in presenting to the EU institutions the reasons to review this Directive, hoping ESMO will indeed take the whelm to stir the oncology community towards a long-lasting, final solution of this anachronistic provision.

ECPC is proud of the strong ties and solid collaboration we have with ESMO and our earlier communication did not aimed at straining such a vital collaboration for us. For this reason, we are sorry for the discomfort that our earlier email might have caused, in particular regarding the timing of the publication of the letter on our website.

One of ECPC's main objective is to provide European cancer patients with the most reliable and updated information available, hence we do make extensive use of our website and social media to share outstanding issues with our patients. Our latest website news item was aimed at creating momentum behind a future political initiative to demand EU policy makers to amend the existing legislation. We sincerely hope that our proactivity will strengthen our future common policy work.

Thanking you again for your prompt reaction and looking forward to reading from you soon.

Kind regards

Francesco De Lorenzo  
ECPC President

Kathi Apostolidis  
ECPC Vice President